Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reiterated a Buy rating on Lucid Diagnostics (NASDAQ:LUCD) and maintained a price target of $2.5.
August 13, 2024 | 10:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson has reiterated a Buy rating on Lucid Diagnostics (NASDAQ:LUCD) and maintained a price target of $2.5.
The reiteration of a Buy rating and the maintenance of a $2.5 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100